The epidemiological trends and projected future of primary sclerosing cholangitis by 2040: An updated meta-analysis and modeling study
PLOS One · 2025
DOI: 10.1371/journal.pone.0322479 ↗Kurz gefasst
Metaanalyse in der Zeitschrift PLOS One, 2025. Verfasst von Meysam Olfatifar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, Iran. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Institute for Gastroenterology and Liver Diseases.
Abstract (Originalsprache)
Background and Aims Primary sclerosing cholangitis (PSC) exhibits varying incidence and prevalence rates across different regions; however, comprehensive global studies examining its geographic distribution and future trends are scarce. This study presents an updated meta-analysis through 2024 and projects the global and regional prevalence of PSC from 2024 to 2040 using an illness-death multi-state model.
Methods
We conducted a thorough systematic search across multiple databases to identify all primary studies published until 2024 that reported on the incidence, prevalence, and mortality rates of PSC in various regions. Using the gathered data, we developed an illness-death model to forecast the future prevalence of PSC, covering the years 2024–2040.
Results
Our meta-analysis revealed that the global pooled incidence and prevalence rates of PSC are 0.65 and 7.52 per 100,000 persons, respectively. Projections indicate that the global prevalence of PSC will rise to 22.98 cases per 100,000 (95% CI: 21.0–24.95), corresponding to an overall increase of 28.3%. Specifically, North America is forecasted to experience a 5.45% increase in PSC cases, reaching 24.76 cases per 100,000 (95% CI: 19.63–29.88), while Western Europe is anticipated to see a more pronounced rise of 28.79%, resulting in a prevalence of 21.48 cases per 100,000 (95% CI: 18.3–24.65) by 2040.
Conclusions
Our findings indicate a substantial rise in the number of individuals affected by PSC in recent years and estimate a significant future burden of the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, Iran.
- Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
- Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Transplant & Hepatobiliary Surgery, Shahid Beheshti University of Medical Sciences,Tehran, Iran.
- Clinical Research Development Center, Qom University of Medical Sciences, Qom, Iran.
- Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Meysam Olfatifar, Hamidreza Houri
Förderung
- Research Institute for Gastroenterology and Liver Diseases
Zitieren
APA
Olfatifar, M., Rajabnia, M., Sadeghi, A., Rabbani, A., Shahrokh, S., Habibi, M. A., Pezeshgi Modarres, M., Zali, M. R., & Houri, H. (2025). The epidemiological trends and projected future of primary sclerosing cholangitis by 2040: An updated meta-analysis and modeling study. PLOS One. https://doi.org/10.1371/journal.pone.0322479
Vancouver
Olfatifar M, Rajabnia M, Sadeghi A, Rabbani A, Shahrokh S, Habibi MA, et al. The epidemiological trends and projected future of primary sclerosing cholangitis by 2040: An updated meta-analysis and modeling study. PLOS One. 2025. doi:10.1371/journal.pone.0322479
BibTeX
@article{Olfatifar2025,
author = {Olfatifar, Meysam and Rajabnia, Mohsen and Sadeghi, Amir and Rabbani, Amirhassan and Shahrokh, Shabnam and Habibi, Mohammad Amin and Pezeshgi Modarres, MehdiSure and Zali, Mohammad Reza and Houri, Hamidreza},
title = {The epidemiological trends and projected future of primary sclerosing cholangitis by 2040: An updated meta-analysis and modeling study},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0322479}
}
EUVIMED